Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

14 апреля 2014 г. обновлено: Bristol-Myers Squibb

A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)

The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban compares with enoxaparin in preventing these clots. The safety of apixaban will also be studied

Обзор исследования

Статус

Завершенный

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

5407

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Австралия
    • New South Wales
      • Camperdown, New South Wales, Австралия, 2050
        • Local Institution
      • Kogarah, New South Wales, Австралия, 2217
        • Local Institution
      • Lismore, New South Wales, Австралия, 2480
        • Local Institution
    • Queensland
      • Southport, Queensland, Австралия, 4215
        • Local Institution
    • South Australia
      • Bedford Park, South Australia, Австралия, 5042
        • Local Institution
    • Victoria
      • Box Hill, Victoria, Австралия, 3128
        • Local Institution
      • Malvern, Victoria, Австралия, 3144
        • Local Institution
      • Windsor, Victoria, Австралия, 3181
        • Local Institution
    • Western Australia
      • Perth, Western Australia, Австралия, 6000
        • Local Institution
  • Аргентина
    • Buenos Aires
      • Capital Federal, Buenos Aires, Аргентина, C1199ACK
        • Local Institution
      • Capital Federal, Buenos Aires, Аргентина, C1280AEB
        • Local Institution
      • Capital Federal, Buenos Aires, Аргентина, C1425AGP
        • Local Institution
      • Ciudad De Buenos Aires, Buenos Aires, Аргентина, C1426BOS
        • Local Institution
      • Coronel Suarez, Buenos Aires, Аргентина, B7540GHD
        • Local Institution
      • Monte Grande, Buenos Aires, Аргентина, B1842DID
        • Local Institution
  • Бельгия
      • Antwerp, Бельгия, 2020
        • Local Institution
      • Brasschaat, Бельгия, 2930
        • Local Institution
      • Genk, Бельгия, 3600
        • Local Institution
      • Hasselt, Бельгия, 3500
        • Local Institution
      • Leuven, Бельгия, 3000
        • Local Institution
  • Венгрия
      • Budapest, Венгрия, 1081
        • Local Institution
      • Kecskemet, Венгрия, 6000
        • Local Institution
      • Szeged, Венгрия, 6720
        • Local Institution
      • Szolnok, Венгрия, 5000
        • Local Institution
  • Германия
      • Frankfurt, Германия, 60528
        • Local Institution
      • Frankfurt / Main, Германия, 65929
        • Local Institution
      • Rheinfelden, Германия, 79618
        • Local Institution
  • Дания
      • Amager, Дания, 2300
        • Local Institution
      • Frederiksberg, Дания, 2000
        • Local Institution
      • Herlev, Дания, 2730
        • Local Institution
      • Horsholm, Дания, 2970
        • Local Institution
      • Hvidovre, Дания, 2650
        • Local Institution
      • Kobenhavn Nv, Дания, 2400
        • Local Institution
      • Silkeborg, Дания, 8600
        • Local Institution
  • Израиль
      • Beer Sheva, Израиль, 84101
        • Local Institution
      • Haifa, Израиль, 31096
        • Local Institution
      • Holon, Израиль, 58100
        • Local Institution
      • Kfar-Saba, Израиль, 44281
        • Local Institution
      • Zerifin, Израиль, 70300
        • Local Institution
  • Индия
      • Bangalore, Индия, 560034
        • Local Institution
      • Mangalore, Индия, 575001
        • Local Institution
    • Gujarat
      • Ahmedabad, Gujarat, Индия, 380015
        • Local Institution
    • Punjab
      • Ludhiana, Punjab, Индия, 141001
        • Local Institution
    • Uttar Prsdesh
      • Lucknow, Uttar Prsdesh, Индия, 226003
        • Local Institution
  • Испания
      • Badalona-Barcelone, Испания, 08916
        • Local Institution
      • Barcelona, Испания, 08035
        • Local Institution
      • Barcelona, Испания, 08036
        • Local Institution
      • Barcelona, Испания, 08006
        • Local Institution
      • Barcelona, Испания, 08024
        • Local Institution
  • Канада
      • Quebec, Канада, G1L 3L5
        • Local Institution
    • Alberta
      • Edmonton, Alberta, Канада, T6G 2B7
        • Local Institution
    • Ontario
      • Ajax, Ontario, Канада, L1S 2J5
        • Local Institution
      • Cambridge, Ontario, Канада, N1R 7L7
        • Local Institution
      • Chatham, Ontario, Канада, N7L 4T1
        • Local Institution
      • Guelph, Ontario, Канада, N1E 6L9
        • Local Institution
      • Newmarket, Ontario, Канада, L3Y 5G8
        • Local Institution
      • Oshawa, Ontario, Канада, L1J 2J2
        • Local Institution
      • Sarnia, Ontario, Канада, N7T 6H3
        • Local Institution
      • Scarborough, Ontario, Канада, M1S 4T7
        • Local Institution
      • St. Catharines, Ontario, Канада, L2R 7P3
        • Local Institution
      • Stratford, Ontario, Канада, N5A 2N4
        • Local Institution
      • Waterloo, Ontario, Канада, N2J 1C4
        • Local Institution
      • Windsor, Ontario, Канада, N8W 1E6
        • Local Institution
    • Quebec
      • Montreal, Quebec, Канада, H3G 1A4
        • Local Institution
  • Китай
    • Beijing
      • Beijing, Beijing, Китай, 100853
        • Local Institution
      • Beijing, Beijing, Китай, 100035
        • Local Institution
    • Guangdong
      • Guangzhou, Guangdong, Китай, 510405
        • Local Institution
    • Shandong
      • Qingdao, Shandong, Китай, 266003
        • Local Institution
    • Shanghai
      • Shanghai, Shanghai, Китай, 200025
        • Local Institution
      • Shanghai, Shanghai, Китай, 200011
        • Local Institution
      • Shanghai, Shanghai, Китай, 200233
        • Local Institution
  • Мексика
      • Aguascalientes, Мексика, 20010
        • Local Institution
      • Chihuahua, Мексика, 31020
        • Local Institution
    • Baja California
      • Tijuana, Baja California, Мексика, 22010
        • Local Institution
    • Distrito Federal
      • Mexico City, Distrito Federal, Мексика, 06726
        • Local Institution
      • Mexico City, Distrito Federal, Мексика, 07760
        • Local Institution
    • Jalisco
      • Guadalajara, Jalisco, Мексика, 45235
        • Local Institution
    • Nuevo Leon
      • Monterrey, Nuevo Leon, Мексика, 64460
        • Local Institution
    • Tamaulipas
      • Cd. Madero, Tamaulipas, Мексика, 89240
        • Local Institution
  • Норвегия
      • Gjettum, Норвегия, 1346
        • Local Institution
      • Kongsvinger, Норвегия, 2212
        • Local Institution
      • Lillehammer, Норвегия, 2629
        • Local Institution
      • Tonsberg, Норвегия, 3116
        • Local Institution
      • Tynset, Норвегия, 2500
        • Local Institution
  • Польша
      • Gdansk, Польша, 80-803
        • Local Institution
      • Lodz, Польша, 91-002
        • Local Institution
      • Szczecin, Польша, 71-252
        • Local Institution
      • Warszawa, Польша, 03-242
        • Local Institution
      • Warszawa, Польша, 02-005
        • Local Institution
      • Wroclaw, Польша, 50-556
        • Local Institution
  • Российская Федерация
      • Chelyabinsk, Российская Федерация, 454021
        • Local Institution
      • Kazan, Российская Федерация, 420029
        • Local Institution
      • Moscow, Российская Федерация, 115522
        • Local Institution
      • Moscow, Российская Федерация, 111539
        • Local Institution
      • Moscow, Российская Федерация, 117292
        • Local Institution
      • Moscow, Российская Федерация, 119415
        • Local Institution
      • Saint Petersburg, Российская Федерация, 199106
        • Local Institution
      • Saint Petersburg, Российская Федерация, 193312
        • Local Institution
      • Saint Petersburg, Российская Федерация, 194354
        • Local Institution
      • Saint Petersburg, Российская Федерация, 195427
        • Local Institution
      • Saint Petersburg, Российская Федерация, 196247
        • Local Institution
      • Samara, Российская Федерация, 443095
        • Local Institution
      • St.Petersburg, Российская Федерация, 192242
        • Local Institution
      • Yaroslavl, Российская Федерация, 150003
        • Local Institution
  • Румыния
      • Bucharest, Румыния, 021659
        • Local Institution
      • Cluj Napoca, Румыния, 400132
        • Local Institution
  • Соединенное Королевство
    • Greater London
      • London, Greater London, Соединенное Королевство, SE5 9RS
        • Local Institution
    • Lancashire
      • Wigan, Lancashire, Соединенное Королевство, WN6 9EP
        • Local Institution
    • Surrey
      • Epsom, Surrey, Соединенное Королевство, KT18 7EG
        • Local Institution
  • Соединенные Штаты
    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35209
        • West Alabama Research, Llc
      • Birmingham, Alabama, Соединенные Штаты, 35209
        • Capstone Clinical Trials, Inc
    • Arkansas
      • Little Rock, Arkansas, Соединенные Штаты, 72205
        • Martin Bowen Hefley Orthopedics
      • Little Rock, Arkansas, Соединенные Штаты, 72205
        • Orthoarkansas, P.A.
    • California
      • Sacramento, California, Соединенные Штаты, 95817
        • UC Davis Medical Center
    • Colorado
      • Aurora, Colorado, Соединенные Штаты, 80012
        • Colorado Orthopedic Consultants, PC
      • Denver, Colorado, Соединенные Штаты, 80230
        • Advanced Orthopedic And Sports Medicine Specilists
      • Denver, Colorado, Соединенные Штаты, 80230
        • Denver-Vail Orthopedics, P.C.
    • Florida
      • Brandon, Florida, Соединенные Штаты, 33511
        • PAB Clinical Research
      • Clearwater, Florida, Соединенные Штаты, 33756
        • Research Alliance, Inc.
      • Ft. Lauderdale, Florida, Соединенные Штаты, 33316
        • Shrock Orthopedic Research
      • Tamarac, Florida, Соединенные Штаты, 33321
        • Phoenix Clinical Research, LLC
    • Georgia
      • Decatur, Georgia, Соединенные Штаты, 30033
        • Atlanta Knee And Sports Medicine
    • Idaho
      • Boise, Idaho, Соединенные Штаты, 83702
        • Americana Orthopedics
      • Meridian, Idaho, Соединенные Штаты, 83642
        • Bosie Orthopedic Clinic
    • Pennsylvania
      • Altoona, Pennsylvania, Соединенные Штаты, 16602
        • University Orthopedic Center
    • Texas
      • Lubbock, Texas, Соединенные Штаты, 79410
        • Gill Orthopedic Center
      • Lubbock, Texas, Соединенные Штаты, 79410
        • Robert R. King, Md
      • San Antonio, Texas, Соединенные Штаты, 78217
        • Unlimited Research
  • Украина
      • Cherkassy, Украина, 18009
        • Local Institution
      • Chernivtsy, Украина, 58013
        • Local Institution
      • Dnipropetrovsk, Украина, 49005
        • Local Institution
      • Ivano-Frankivsk, Украина, 76008
        • Local Institution
      • Kyiv, Украина, 01601
        • Local Institution
      • Kyiv, Украина, 04107
        • Local Institution
      • Sevastopol, Украина, 99018
        • Local Institution
  • Франция
      • Nice, Франция, 06200
        • Local Institution
      • Paris, Франция, 75014
        • Local Institution
      • Paris, Франция, 75019
        • Local Institution
      • Paris, Франция, 75679
        • Local Institution
      • Saint Etienne, Франция, 42100
        • Local Institution
      • Saint-Saulve, Франция, 59880
        • Local Institution
  • Швеция
      • Gothenburg, Швеция, 416 85
        • Local Institution
      • Stockholm, Швеция, 182 88
        • Local Institution

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Key Inclusion Criteria

  • Patients undergoing elective unilateral total hip replacement or a revision of at least 1 component of a total hip replacement.
  • Patients who were willing and able to undergo bilateral ascending contrast venography
  • Either sex, any race, 18 years and older

Key Exclusion Criteria

  • Known or suspected bleeding or coagulation disorder in the patient or his or her first-degree relative
  • Known or suspected history of heparin-induced thrombocytopenia
  • Known coagulopathy
  • Active bleeding or at high risk for bleeding
  • Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days
  • Active hepatobiliary disease
  • Alcohol and/or substance abuse within the past year
  • Any condition for which surgery or administration of an anticoagulant is contraindicated
  • Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure >180 mm Hg or supine diastolic blood pressure >105 mm Hg
  • Clinically significant laboratory abnormalities at the enrollment visit:
  • Hemoglobin <10 g/dL
  • Platelet count <100,000/mm^3
  • Creatinine clearance <30 mL/min, as estimated by the method of Cockcroft and Gault
  • Alanine aminotransferase or aspartate aminotransferase >2*upper limit of normal or a total bilirubin ≥ 1.5*1 (unless an alternative causative factor such as Gilbert's syndrome was identified)
  • Need for ongoing treatment with a parenteral or oral anticoagulant (eg, subjects with mechanical valves, warfarin eligible atrial fibrillation)
  • Current use of dextrans or fibrinolytics
  • Treatment with medications affecting coagulation or platelet function

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Профилактика
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Двойной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Активный компаратор: Apixaban, 2.5 mg BID plus placebo
Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
Лекарство: Apixaban
Oral tablets, 2.5 mg, twice daily, 5weeks
Другие имена:
  • БМС-562247
  • Эликвис®
Лекарство: Enoxaparin-matching placebo
Administered as injection
Экспериментальный: Enoxaparin, 40 mg QD plus placebo
Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
Лекарство: Enoxaparin
Subcutaneous, 40 mg, once daily, 5 weeks
Другие имена:
  • Лавенокс®
Лекарство: Apixaban-matching placebo
Administered as oral tablets

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period
Временное ограничение: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization.
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period
Временное ограничение: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined.
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period
Временное ограничение: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated.
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome
Временное ограничение: First dose of study drug (presurgery) through 30 days after the last dose of study drug
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood.
First dose of study drug (presurgery) through 30 days after the last dose of study drug
Number of Participants With a Bleeding-related Adverse Event During the Treatment Period
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients.
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: >2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): <0.75*preRx; platelet count (*10^9 cells/L): <100,000/mm^3; erythrocytes (*10^6 cells/μL): <0.75*preRx level; leukocytes (*10^3 cells/μL): < 0.75*LLN or >1.25*ULN, or if preRx LLN use < 0.8*preRx or >ULN if preRx >ULN use >1.2*preRx or <LLN; basophils (*10^3 cells/μL): >400/mm^3; eosinophils (*10^3 cells/μL): > 0.75*10^3 cells/μL; lymphocytes (*10^3 cells/μL): >0.75*10^3 cells/μL; monocytes (*10^3 cells/μL): >2000/mm^3; neutrophils (*10^3 cells/μL): <1.0;
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): >3 *ULN: alkaline phosphatase (ALP) (U/L): >2* ULN; aspartate aminotransferase (ASP) (U/L): >3 *ULN; bilirubin, direct (mg/dL): >2*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN; calcium (mg/dL): < 0.8*LLN or >1.2 *ULN, or if preRx <LLN use <0.75* preRx or >ULN if preRx >ULN use > 1.25*preRx or <LLN; chloride (mEq/L): <0.9*LLN or >1.1*ULN, or if preRx <LLN use <0.9*preRx or >ULN if preRx >ULN use >1.1* preRx or <LLN; bicarbonate (mEq/L): < 0.75* LLN or >1.25*ULN, or if preRx <LLN use <0.75*preRx or >ULN if preRx >ULN use >1.25*preRx or <LLN; potassium (mEq/L): < 0.9*LLN or >1.1*ULN, or if preRx <LLN use <0.9*preRx or >ULN if preRx >ULN use >1.1* preRx or < LLN; sodium (mEq/L): <0.95* LLN or >1.05×ULN, or if preRx <LLN use <0.95* predose or >ULN if preRx >ULN use >1.05 *preRx or < LLN.
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
Временное ограничение: First dose of study drug (presurgery) through 2 days after the last dose of study drug
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): <.8*LLN or >1.5*ULN, or if preRx <LLN use <.8*preRx or >ULN if preRx >ULN use >2*preRx or <LLN; protein, total (g/L): If missing preRx use ≥2, or if value ≥4 or preRx =0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; creatine kinase (U/L): >5*ULN; uric acid (mg/dL): >.5* ULN, or if preRx >ULN use >2*preRx; blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; glucose, urine : If missing preRx use ≥2, or if value ≥4, or if preRx=0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; RBC, urine (hpf): If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx dose= 1 use ≥3, or if preRx=2 or 3 use ≥4; WBC, urine (h): If missing preRx use ≥2, or if value ≥4, or if preRx =0 or .5 use ≥2, or if preRx =1 use ≥3, or if preRx=2 or 3 use ≥4.
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period
Временное ограничение: First dose of study drug (presurgery) through 30 days after the last dose of study drug
Treatment guidelines were provided for jaundice and elevated results of liver function tests.
First dose of study drug (presurgery) through 30 days after the last dose of study drug
Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period
Временное ограничение: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to <100,000/mm^3 for patients with a baseline value >150,000/mm^3 or a >50% decline, if the baseline value was ≤150,000/mm^3.
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Bristol-Myers Squibb

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования

1 марта 2007 г.

Первичное завершение (Действительный)

1 сентября 2009 г.

Завершение исследования (Действительный)

1 сентября 2009 г.

Даты регистрации исследования

Первый отправленный

17 января 2007 г.

Впервые представлено, что соответствует критериям контроля качества

17 января 2007 г.

Первый опубликованный (Оценивать)

18 января 2007 г.

Обновления учебных записей

Последнее опубликованное обновление (Оценивать)

14 мая 2014 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

14 апреля 2014 г.

Последняя проверка

1 апреля 2014 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • CV185-035

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться